HER2-positives Ösophageal/GEJ Adenokarzinom, das nach Magenkriterien bewertet wird: Trastuzumab + che...
Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.
| ID | BMA-HER2-AMP-ESOPHAGEAL |
|---|---|
| Art | Therapeutische Relevanz |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Erkrankungen | DIS-ESOPHAGEAL |
| Quellen | SRC-ESMO-ESOPHAGEAL-2024 SRC-NCCN-ESOPHAGEAL-2025 |
Fakten zur Handlungsfähigkeit
| Biomarker | BIO-HER2-SOLID |
|---|---|
| Variante | Verstärkung/Überexpression — IHC 3+ oder (IHC 2+ + ISH verstärkt) unter Anwendung von Kriterien des Magenhofmann 2008; ~10-30% des Äsophagetals/GEJ Adenokarzinoms |
| Erkrankung | DIS-ESOPHAGEAL |
| ESCAT-Stufe | IA |
| Empfohlene Kombinationen | trastuzumab + fluoropyrimidine + platinum (1L per SRC-NCCN-ESOPHAGEAL-2025, SRC-ESMO-ESOPHAGEAL-2024), pembrolizumab + trastuzumab + fluoropyrimidine + platinum (1L HER2+ PD-L1 CPS≥1 GEJ adenocarcinoma per SRC-NCCN-ESOPHAGEAL-2025), trastuzumab deruxtecan (2L+ per SRC-NCCN-ESOPHAGEAL-2025) |
| Kontraindizierte Monotherapie | Trastuzumab Monotherapie, Anti-HER2-Therapie bei Plattenepithel-Esophagealkarzinom |
| Zusammenfassung der Beweise | HER2-positive esophageal/GEJ adenocarcinoma scored by gastric criteria: trastuzumab + chemotherapy is preferred 1L (cross-referenced from ToGA / KEYNOTE-811) per SRC-NCCN-ESOPHAGEAL-2025, SRC-ESMO-ESOPHAGEAL-2024. Pembrolizumab + trastuzumab + fluoropyrimidine/platinum is FDA-approved for HER2+ PD-L1 CPS≥1 metastatic GEJ adenocarcinoma (KEYNOTE-811). Trastuzumab deruxtecan is FDA-approved 2L+ for HER2-positive advanced gastric/GEJ adenocarcinoma (DESTINY-Gastric01 includes Siewert types). Squamous-cell esophageal carcinoma is HER2-negative as a rule and is not in scope for HER2-directed therapy. |
Anmerkungen
ESCAT IA / OncoKB Level 1. HER2 testing for adenocarcinoma histology only (not squamous). Heterogeneity high — ≥4 biopsies recommended. Bibliographic record SRC-DESTINY-GASTRIC01-SHITARA-2020 is available; SRC-TOGA-BANG-2010 and SRC-KEYNOTE-811 remain source gaps. Claim-level linkage requires clinical sign-off.
Verwendet von
Keine Rückverweise im YAML-Korpus gefunden.